<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>vaccines on FinanClub</title>
    <link>https://finan.club/tags/vaccines/</link>
    <description>Recent content in vaccines on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 22 Jan 2024 09:05:50 +0000</lastBuildDate><atom:link href="https://finan.club/tags/vaccines/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Mon, 22 Jan 2024 09:05:50 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:153
Chances: Merck &amp;amp; Co., Inc. has a strong portfolio of pharmaceutical, vaccine, and animal health products, positioning it well for future growth and profitability. The recent FDA approval for expanded use of Keytruda in combination with chemoradiotherapy for advanced cervical cancer is a significant positive development for the company.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
